Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD 由 Fletcher, RA, Herrington, WG, Agarwal, R, Mayne, KJ, Arnott, C, Jardine, MJ, Mahaffey, KW, Perkovic, V, Staplin, N, Wheeler, DC, Chertow, GM, Heerspink, HJL, Neuen, BL

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis 由 Patel, SM, Kang, YM, Im, K, Neuen, BL, Anker, SD, Bhatt, DL, Butler, J, Cherney, DZI, Claggett, BL, Fletcher, RA, Herrington, WG, Inzucchi, SE, Jardine, MJ, Mahaffey, KW, McGuire, DK, McMurray, JJV, Neal, B, Packer, M, Perkovic, V, Solomon, SD, Staplin, N, Vaduganathan, M, Wanner, C, Wheeler, DC, Zannad, F, Zhao, Y, Heerspink, HJL, Sabatine, MS, Wiviott, SD

2017 cardiovascular and stroke endpoint definitions for clinical trials 由 Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials 由 Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MTT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ, Standardized Data Collection For Cardiovascular Trials Initiative (Scti)